Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NASDAQ:NTRA), executed a transaction on May 26, 2026, involving the sale of company common stock valued at $335,091.
The specifics of the divestiture indicate that Mr. Moshkevich sold 1,652 shares of Natera's common stock, with each share priced at $202.84. This sale was explicitly conducted to cover tax withholding and remittance obligations associated with the vesting of restricted stock units (RSUs). The transaction followed a written instruction designed to meet the affirmative defense conditions outlined in Rule 10b5-1(c) under the Exchange Act, which pertains to Mr. Moshkevich's Stock Unit Agreement that was initially granted on June 10, 2022.
As of the time of the filing, Natera's common stock had increased in value to $213.94, representing a strong gain of 35% over the past year, despite facing recent market fluctuations. Following this transaction, Mr. Moshkevich maintained an ownership stake of 140,643 shares of Natera common stock. The public filing detailing these sales was made available on May 28, 2026.
Beyond the insider trading activity, recent corporate disclosures provide a detailed look into Natera's operational and financial standing. For the first quarter of 2026, Natera Inc. reported mixed financial outcomes. The company managed to achieve total revenue of $696.64 million, surpassing the consensus expectation of $617.2 million. This revenue figure represents a significant increase of 39% when compared directly to the revenue generated in the previous year.
However, the financial performance was not uniformly positive across all metrics. The earnings per share (EPS) for the quarter registered at -$0.60, which failed to meet the anticipated EPS estimate of -$0.54.
Operational Highlights and Growth Vectors
Despite the mixed quarterly results, Natera highlighted several areas of technological advancement and expansion. The company announced a notable enhancement to its Panorama non-invasive prenatal test. This upgrade utilizes advanced sequencing technology, which has resulted in reducing the no-call rate down to 0.5%. In addition to product improvements, Natera is significantly increasing its scientific visibility by presenting 35 oncology abstracts at the 2026 American Society of Clinical Oncology Annual Meeting. These presentations will concentrate on molecular residual disease testing.
On an infrastructure and growth front, Natera plans a major expansion of its North Austin headquarters. This facility upgrade is projected to add approximately 400 new jobs and substantially increase the company's existing sequencing capacity. Furthermore, clinical trial progress remains robust; the EXPAND clinical trial has successfully enrolled over 2,000 patients, which marks a doubling of participation levels compared to the previous year.
Market Valuation Context
From an external valuation perspective, InvestingPro analysis currently suggests that Natera appears to be valued at a premium relative to its calculated Fair Value. This assessment is based on the company carrying a reported market capitalization of $30.6 billion.